Maria Cecilia Hospital, GVM Care & Research, Cotignola, 48033 Ravenna, Italy.
Department of Medical Sciences, Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, 44121 Ferrara, Italy.
Int J Mol Sci. 2020 Jul 11;21(14):4899. doi: 10.3390/ijms21144899.
Calcific aortic stenosis is a disorder that impacts the physiology of heart valves. Fibrocalcific events progress in conjunction with thickening of the valve leaflets. Over the years, these events promote stenosis and obstruction of blood flow. Known and common risk factors are congenital defects, aging and metabolic syndromes linked to high plasma levels of lipoproteins. Inflammation and oxidative stress are the main molecular mediators of the evolution of aortic stenosis in patients and these mediators regulate both the degradation and remodeling processes. Mitochondrial dysfunction and dysregulation of autophagy also contribute to the disease. A better understanding of these cellular impairments might help to develop new ways to treat patients since, at the moment, there is no effective medical treatment to diminish neither the advancement of valve stenosis nor the left ventricular function impairments, and the current approaches are surgical treatment or transcatheter aortic valve replacement with prosthesis.
钙化性主动脉瓣狭窄是一种影响心脏瓣膜生理学的疾病。纤维钙化事件与瓣叶增厚同时发生。多年来,这些事件会导致狭窄和血液流动受阻。已知的常见风险因素包括先天性缺陷、衰老和与脂蛋白血浆水平升高相关的代谢综合征。炎症和氧化应激是患者主动脉瓣狭窄演变的主要分子介质,这些介质调节降解和重塑过程。线粒体功能障碍和自噬失调也与该疾病有关。更好地了解这些细胞损伤可能有助于开发新的治疗方法,因为目前尚无有效的医学治疗方法来减轻瓣膜狭窄的进展或左心室功能障碍,目前的方法是手术治疗或使用假体进行经导管主动脉瓣置换。